Transenterix Inc (NYSEAMERICAN:TRXC) was the recipient of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 19,972,997 shares, an increase of 14.9% from the February 15th total of 17,376,442 shares. Based on an average daily trading volume, of 3,257,988 shares, the days-to-cover ratio is presently 6.1 days. Approximately 45.3% of the shares of the stock are short sold.
Transenterix (NYSEAMERICAN:TRXC) traded down $0.02 during midday trading on Friday, reaching $1.64. 1,371,207 shares of the company’s stock traded hands, compared to its average volume of 2,518,821. Transenterix has a 12-month low of $0.45 and a 12-month high of $5.00. The stock has a market cap of $354.65, a PE ratio of -1.84 and a beta of 2.12.
A number of hedge funds have recently made changes to their positions in TRXC. Ladenburg Thalmann Financial Services Inc. lifted its stake in Transenterix by 87.8% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 79,150 shares of the medical instruments supplier’s stock worth $113,000 after acquiring an additional 37,000 shares during the period. Raymond James Financial Services Advisors Inc. purchased a new position in Transenterix during the fourth quarter valued at $113,000. Bank of New York Mellon Corp lifted its position in Transenterix by 94.0% during the fourth quarter. Bank of New York Mellon Corp now owns 119,584 shares of the medical instruments supplier’s stock valued at $231,000 after buying an additional 57,944 shares during the period. BlackRock Inc. lifted its position in Transenterix by 157.3% during the fourth quarter. BlackRock Inc. now owns 1,760,266 shares of the medical instruments supplier’s stock valued at $3,397,000 after buying an additional 1,076,133 shares during the period. Finally, Virtu Financial LLC purchased a new position in Transenterix during the fourth quarter valued at $109,000.
Several research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Transenterix from a “sell” rating to a “hold” rating in a research report on Tuesday, January 23rd. BTIG Research reiterated a “hold” rating on shares of Transenterix in a research report on Monday, December 18th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $2.61.
Transenterix Company Profile
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
Receive News & Ratings for Transenterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix and related companies with MarketBeat.com's FREE daily email newsletter.